|1.||Bae, Yoe-Sik: 5 articles (03/2014 - 02/2002)|
|2.||Kim, Jae Ho: 3 articles (10/2015 - 03/2014)|
|3.||Heo, Soon Chul: 3 articles (10/2015 - 03/2014)|
|4.||Jang, Il Ho: 3 articles (10/2015 - 03/2014)|
|5.||Kwon, Yang Woo: 3 articles (10/2015 - 03/2014)|
|6.||Baek, Suk-Hwan: 3 articles (01/2013 - 10/2010)|
|7.||Lee, Ha Young: 3 articles (01/2013 - 10/2010)|
|8.||Kim, Sang Doo: 3 articles (01/2013 - 10/2010)|
|9.||Ryu, Sung Ho: 3 articles (10/2010 - 02/2002)|
|10.||Yoon, Jung Won: 2 articles (07/2015 - 03/2014)|
03/01/2014 - "Intramuscular injection of WKYMVm resulted in attenuation of severe hind limb ischemia and promoted neovascularization in ischemic limb. "
10/01/2015 - "When WKYMVm peptide encapsulated microspheres were injected into the hind limb ischemia model, a single injection of microspheres was as effective as multiple injections of WKYMVm peptide in restoring blood flow from ischemic injury and promoting capillary growth. "
10/01/2015 - "In this study, highlight the efficacy of WKYMVm peptide's role in inducing neovascularization in vivo hind limb ischemia model when the peptide was released from injected PLGA microspheres in sustained manner. "
06/01/2014 - "Decreased number of myeloid-derived suppressor cells (MDSCs) and increased NK cell infiltration in tumor tissues were detected from WKYMVm-treated mice. "
01/01/2012 - "Here, we examined the effects of administering an immune stimulating peptide (WKYMVm), 5-fluoro-uracil (5-FU), and mature dendritic cells (mDCs) against heterotopic cancer animal model. "
01/01/2012 - "A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model."
05/01/2008 - "We have previously shown that the novel hexapeptide WKYMVm can stimulate bactericidal activity in neutrophils obtained from neutropenic patients treated with chemotherapeutic agents for solid tumors. "
04/01/2006 - "In this study, we evaluate whether WKYMVm stimulates bactericidal activity in neutrophils obtained from patients who received chemotherapy for solid tumors when they were neutropenic. "
|3.||Wounds and Injuries (Trauma)
07/01/2015 - "These results suggest that WKYMVm has therapeutic effects on diabetic wounds by stimulating angiogenesis and infiltration of immune cells. "
07/01/2015 - "Topical application of WKYMVm onto cutaneous wounds stimulated formation of von Willebrand factor-positive capillary and α-smooth muscle actin-positive arteriole with a maximal stimulation on day 6, suggesting WKYMVm-stimulated angiogenesis. "
07/01/2015 - "In this study, we explored the therapeutic effects of WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met-NH2), a synthetic peptide agonist of formyl peptide receptor 2, on cutaneous wounds in streptozotocin-induced diabetic rats. "
|4.||Melanoma (Melanoma, Malignant)
06/01/2014 - "Growth of melanoma cell line B16-F10 was significantly inhibited in WKYMVm-treated mice and markedly promoted in WRW(4)-treated mice compared with control. "
06/01/2014 - "In our current study, wild-type mice were inoculated with melanoma cell line B16-F10 (1 × 10(6)/mouse) and treated with the formyl peptide receptor (FPR) agonist WKYMVm or the FPR antagonist WRW(4). "
01/01/2013 - "In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. "
01/01/2013 - "The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis."
01/01/2013 - "The WKYMVm-induced therapeutic effect against ulcerative colitis was strongly inhibited by a formyl peptide receptor (FPR) 2 antagonist, WRWWWW, indicating the crucial role of FPR2 in this effect. "
|1.||polylactic acid-polyglycolic acid copolymer (PLGA)
|2.||Formyl Peptide Receptors (Formyl Peptide Receptor)
|4.||NADPH Oxidase (NAD(P)H oxidase)
|5.||Interleukin-1alpha (Interleukin 1 alpha)
|7.||Reactive Oxygen Species (Oxygen Radicals)
|8.||von Willebrand Factor
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Glial Fibrillary Acidic Protein
|2.||Drug Therapy (Chemotherapy)